Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Setmelanotide Acetate
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Rhythm Pharmaceuticals
Deal Size : $6.3 million
Deal Type : Termination
Rhythm Reacquires IMCIVREE® China Rights with RareStone Agreement Termination
Details :
Product Name : Imcivree
Product Type : Peptide
Upfront Cash : $6.3 million
March 20, 2025
Lead Product(s) : Setmelanotide Acetate
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Rhythm Pharmaceuticals
Deal Size : $6.3 million
Deal Type : Termination
Lead Product(s) : Pitolisant Hydrochloride
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
China NMPA Approves RareStone's Pitolisant (Wakix) for the Treatment of Narcolepsy
Details :
Product Name : Wakix
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 07, 2023
Lead Product(s) : Pitolisant Hydrochloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pitolisant Hydrochloride
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Wakix (pitolisant hydrochloride), a selective histamine H3-receptor antagonist/inverse agonist, is approved by the EMA and the FDA to treat adults suffering from narcolepsy, a serious, chronic disorder characterized by excessive daytime sleepiness, with ...
Product Name : Wakix
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 21, 2021
Lead Product(s) : Pitolisant Hydrochloride
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable